title: Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women?
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Clarkson
authors.forename: Richard H
authors.initials: RH
authors.lastname: Karas
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D004195:Disease Models, Animal; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008593:Menopause; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D004967:Estrogens